Patents by Inventor Kai Singbartl
Kai Singbartl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240118289Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: ApplicationFiled: May 22, 2023Publication date: April 11, 2024Inventors: Kai Singbartl, John A. Kellum
-
Patent number: 11693014Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: GrantFiled: January 15, 2020Date of Patent: July 4, 2023Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Kai Singbartl, John A. Kellum, Jr.
-
Publication number: 20200150132Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: ApplicationFiled: January 15, 2020Publication date: May 14, 2020Inventors: Kai Singbartl, John A. Kellum, JR.
-
Patent number: 10557856Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: GrantFiled: September 16, 2011Date of Patent: February 11, 2020Assignee: University Of Pittsburgh-Of The Commonwealth System Of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.
-
Publication number: 20190227056Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of hyaluronic acid (HA) as diagnostic and prognostic biomarker assays in renal injuries.Type: ApplicationFiled: January 18, 2019Publication date: July 25, 2019Applicants: ASTUTE MEDICAL, INC., THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: JOSEPH ANDERBERG, JEFF GRAY, PAUL MCPHERSON, KEVIN NAKAMURA, JAMES PATRICK KAMPF, KAI SINGBARTL, JOHN A. KELLUM
-
Patent number: 10258734Abstract: A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.Type: GrantFiled: March 8, 2017Date of Patent: April 16, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: William J. Federspiel, John Alston Kellum, Kai Singbartl
-
Publication number: 20170199204Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.Type: ApplicationFiled: January 6, 2017Publication date: July 13, 2017Inventors: Kai Singbartl, John A. Kellum
-
Publication number: 20170173254Abstract: A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.Type: ApplicationFiled: March 8, 2017Publication date: June 22, 2017Inventors: WILLIAM J. FEDERSPIEL, JOHN ALSTON KELLUM, KAI SINGBARTL
-
Publication number: 20170074868Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of hyaluronic acid (HA) as diagnostic and prognostic biomarker assays in renal injuries.Type: ApplicationFiled: November 7, 2016Publication date: March 16, 2017Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf, Kai Singbartl, John A. Kellum
-
Patent number: 9551720Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.Type: GrantFiled: January 20, 2012Date of Patent: January 24, 2017Assignee: University of Pittsburgh—Of the Commonwaelth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.
-
Patent number: 9389222Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: GrantFiled: May 27, 2015Date of Patent: July 12, 2016Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER LEARNINGInventors: Kai Singbartl, John A. Kellum
-
Publication number: 20150330975Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: ApplicationFiled: May 27, 2015Publication date: November 19, 2015Inventors: Kai Singbartl, John A. Kellum
-
Publication number: 20150241415Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect hyaluronic acid as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.Type: ApplicationFiled: August 9, 2013Publication date: August 27, 2015Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf, Kai Singbartl, John A. Kellum, JR.
-
Patent number: 9057722Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: GrantFiled: July 15, 2014Date of Patent: June 16, 2015Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum
-
Publication number: 20140329256Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Inventors: Kai Singbartl, John A. Kellum
-
Patent number: 8815602Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: GrantFiled: July 18, 2013Date of Patent: August 26, 2014Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum
-
Publication number: 20130323751Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.Type: ApplicationFiled: January 20, 2012Publication date: December 5, 2013Applicant: University of Pittsburgh - of the Common-Wealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, JR.
-
Publication number: 20130299427Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: ApplicationFiled: July 18, 2013Publication date: November 14, 2013Inventors: Kai Singbartl, John A. Kellum
-
Publication number: 20130252264Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of hyaluronic acid (HA) as diagnostic and prognostic biomarker assays in renal injuries.Type: ApplicationFiled: September 23, 2011Publication date: September 26, 2013Applicant: Astute Medical, Inc.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf, Kai Singbartl, John A. Kellum
-
Patent number: 8501489Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: GrantFiled: September 23, 2009Date of Patent: August 6, 2013Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.